Rezultati pretraživanja
  1. 29. sij
  2. 29. sij
  3. 29. sij
  4. 1. lis 2019.
  5. 4. kol 2019.
  6. 24. tra 2019.
  7. 22. ožu 2019.

    (-54.3% pre) Conatus Pharma's emricasan flunks late-stage NASH study - SA

  8. 12. velj 2019.

    Completes Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated Cirrhosis. Top line results in mid 2019

  9. 29. sij 2019.
  10. 27. sij 2019.

    Commented on - Update On NASH Antifibrotics:?sht=plzivw&shu=l8mmr Allergan, Gilead, Conatus, Galectin

  11. Been just over a year since I published my first article on . Posted a brief, new write-up on following conference – Viking Therapeutics: Year In Review

  12. 4. ruj 2018.
  13. 26. tra 2018.
    Prikaži ovu nit
  14. 18. tra 2018.

    (+2.7% pre) Conatus Pharma's IDN-7314 shows encouraging action in preclinical studies - SA

  15. 5. tra 2018.

    (-28.5% pre) Conatus Pharma shares fall on liver-drug study data - MW

  16. 5. sij 2018.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.